In Reply Drs Suissa and Ernst correctly note that we inadvertently erred in describing the follow-up period used in their study.1 Also, we agree that our wording could have been interpreted as implying that their study primarily or exclusively evaluated patients who died of pneumonia and that they did not adjust for LABA use, which is incorrect and was not our intended meaning. These points have been clarified in the online version of the article’s supplement.
Gershon AS, Campitelli MA, Stanbrook MB. Long-Acting β-Agonists With vs Without Inhaled Corticosteroids for COPD—Reply. JAMA. 2015;313(3):305-306. doi:10.1001/jama.2014.16479